淋巴瘤

预约门诊

淋巴瘤生存率

不同类型淋巴瘤的生存率各不相同。生存率还取决于您的整体健康状况、癌症分期以及所接受的治疗方案。为了解淋巴瘤的生存率，专家会研究大量淋巴瘤患者，观察他们在确诊后 5 年内的存活人数。

对于 1 期霍奇金淋巴瘤，患者确诊后至少存活 5 年的概率为 92%。随着癌症扩散，存活概率会降低。对于 4 期霍奇金淋巴瘤，患者确诊后至少存活 5 年的概率约为 82%。

对于 1 期非霍奇金淋巴瘤，患者确诊后至少存活 5 年的概率为 87%。随着癌症扩散，存活概率会降低。对于 4 期非霍奇金淋巴瘤，患者确诊后至少存活 5 年的概率约为 63%。

需注意生存统计数据需要 5 年时间采集。最新的生存率数据包含 5 年前接受过淋巴瘤治疗的患者。这些患者可能未接触过最新疗法。在过去数十年间，淋巴瘤的死亡率持续下降，生存率稳步提升。

申请预约
分期医生与科室
Jan. 13, 2026

Living with 淋巴瘤?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

mjlandin
Does anyone else have MGUS?

1138 Replies Tue, Feb 10, 2026

amyboylan1
Is there anything to help stop or slow progression of MGUS?

172 Replies Tue, Feb 10, 2026

See more discussions
  1. Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq. Accessed Aug. 6, 2025.
  2. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Aug. 6, 2025.
  3. Primary CNS lymphoma treatment (PDQ) — Patient version https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq. Accessed Aug. 6, 2025.
  4. Mycosis fungoides (including Sezary Syndrome) treatment (PDQ) — Patient version https://www.cancer.gov/types/lymphoma/patient/mycosis-fungoides-treatment-pdq. Accessed Aug. 6, 2025.
  5. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Aug. 6, 2025.
  6. Cancer stat facts: Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/hodg.html. Accessed Aug. 6, 2025.
  7. Elsevier Point of Care. Clinical Overview: Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  8. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  9. Niederhuber JE, et al., eds. Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  10. Larson RA, et al. Tumor lysis syndrome: Prevention and treatment. https://www.uptodate.com/contents/search. Accessed Aug. 6, 2025.
  11. Elsevier Point of Care. Clinical Overview: Febrile neutropenia in adults. https://www.clinicalkey.com. Accessed Aug. 6, 2025.
  12. Robetorye R, et al. Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx Testing) into the routine work-up of diffuse large B-cell lymphoma. Journal of Hematopathology. 2019; doi:10.1007/s12308-019-00344-0.
  13. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  14. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Aug. 6, 2025.
  15. Membership institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Aug. 6, 2025.

相关

相关医疗程序

产品与服务

淋巴瘤

CON-20304579